New option available for Alzheimer’s patients as FDA approves expanded drug use
The FDA has approved Auvelity as the first non-antipsychotic treatment for agitation in Alzheimer's disease, marking a major milestone for patients.
Browse Tag
1d48c920-4df5-548e-a84a-0048423f809a
1 Article